Performance Evaluation of the OraQuick Hepatitis C Virus Rapid Antibody Test

6, Gwacheon, Korea Background: A reliable rapid assay for hepatitis C virus (HCV) may be helpful in various clinical settings. We evaluated the performance of the OraQuick HCV Rapid Antibody Test (OraSure Technologies Inc., Bethlehem, PA, USA). Methods: Clinical sensitivity and specifi city were evaluated with oral fl uids and sera from 137 patients diagnosed with hepatitis C and 300 healthy blood donors in a multi-center collaborative study. The stored sera of 200 proven HCV-infected patients and 200 healthy subjects were also evaluated. Analytical sensitivity was estimated with 4 commercial seroconversion panels and 7 Korean reference panels. The performance of 4 laboratory-based tests (3 chemiluminescence assays and 1 enzyme immunoassay) and 4 rapid test kits was compared. We also assessed the interference due to bilirubin, hemoglobin, lipid, rheumatoid factor, multipara, and several viral infections. Results: The clinical sensitivity and specifi city of the OraQuick HCV test using oral fl uid were 97.8% (95% confi dence interval [CI], 93.2-99.4%) and 100% (95% CI, 98.4-100%), respectively. The clinical sensitivity using serum samples was 100%. Using the 4 seroconversion panels, the OraQuick HCV test showed results comparable to those of the laboratory-based assays; its analytical sensitivity was higher than that of the other rapid test kits. There was no cross-reactivity with common interfering factors. Conclusions: The clinical performance of the OraQuick HCV Test is comparable to that of laboratory-based tests with both serum and oral fl uid. This supports the supplementary use of rapid HCV testing using oral fl uid in various medical and non-medical settings.